A novel treatment for refractory dermatomyositis: A systematic review of anifrolumab and dermatomyositis - 17/07/25
Doi : 10.1016/j.jaad.2025.04.025
Anagha Srivatsa, BS a, ⁎ 
, Wasey Rehman, BS b, Rafey Rehman, MD c, Meena Moossavi, MD c, Steven Daveluy, MD c, Geoffrey Potts, MD c
, Wasey Rehman, BS b, Rafey Rehman, MD c, Meena Moossavi, MD c, Steven Daveluy, MD c, Geoffrey Potts, MD c a Wayne State University School of Medicine, Detroit, Michigan
b University of Michigan-Dearborn, Dearborn, Michigan
c Department of Dermatology, Wayne State University, Detroit, Michigan
∗Correspondence to: Anagha Srivatsa, BS, Wayne State University School of Medicine, 540 E Canfield St, Detroit, MI 48201Wayne State University School of Medicine540 E Canfield StDetroitMI48201
Key words : anifrolumab, dermatomyositis
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 93 - N° 2
P. 543-546 - août 2025 Retour au numéro
Article précédent
- State-based insurance coverage access to laser hair reduction for the treatment of pseudofolliculitis barbae: An evaluation of public and private policies
- Rohan Ahuja, Christine Olagun-Samuel, Elijah Rodriguez, Rebecca Vasquez, Prince Adotama
- An analysis of the impact of program signals and geographic preferences on interview invites for the dermatology match process
- Anjali J. D'Amiano, Jack Kollings, Vrinda Madan, Joel Sunshine
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?